Literature DB >> 1717717

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

M Thali1, U Olshevsky, C Furman, D Gabuzda, M Posner, J Sodroski.   

Abstract

While one hypervariable, linear neutralizing determinant on the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein has been well characterized, little is known about the conserved, discontinuous gp120 epitopes recognized by neutralizing antibodies in infected individuals. Here, the epitope recognized by a broadly reactive neutralizing monoclonal antibody (F105) derived from an HIV-1-infected patient was characterized by examining the effects of changes in conserved gp120 amino acids on antibody reactivity. The F105 epitope was disrupted by changes in gp120 amino acids 256 and 257, 368 to 370, 421, and 470 to 484, which is consistent with the discontinuous nature of the epitope. Three of these regions are proximal to those previously shown to be important for CD4 binding, which is consistent with the ability of the F105 antibody to block gp120-CD4 interaction. Since F105 recognition was more sensitive to amino acid changes in each of the four identified gp120 regions than was envelope glycoprotein function, replication-competent mutant viruses that escaped neutralization by the F105 antibody were identified. These studies identify a conserved, functional HIV-1 gp120 epitope that is immunogenic in man and may serve as a target for therapeutic or prophylactic intervention.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717717      PMCID: PMC250310     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity.

Authors:  C B Pert; J M Hill; M R Ruff; R M Berman; W G Robey; L O Arthur; F W Ruscetti; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.

Authors:  P L Nara; W G Robey; L O Arthur; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek; P J Fischinger
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

3.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

4.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.

Authors:  A Cordonnier; L Montagnier; M Emerman
Journal:  Nature       Date:  1989-08-17       Impact factor: 49.962

5.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.

Authors:  B S Stein; S D Gowda; J D Lifson; R C Penhallow; K G Bensch; E G Engleman
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

10.  Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; J Li; J Sodroski
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more
  112 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 6.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

7.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.